In short
Researchers are exploring the potential of Alkaline Phosphatase, Bovine (bRESCAP) in reducing complications associated with kidney transplants. This Phase 2 clinical trial aims to investigate whether this drug can prevent ischemia reperfusion injury and decrease the duration of delayed graft function (DGF) in patients receiving kidneys from donors after circulatory death. The study focuses on improving outcomes for individuals with end-stage kidney disease undergoing transplantation.
At a glance
- Drug Name
- Alkaline Phosphatase, Bovine (bRESCAP)
- Trial Phase
- Phase 2
- Main Objective
- Prevent ischemia reperfusion injury and decrease delayed graft function duration
- Target Population
- End-stage kidney disease patients receiving transplants from donors after circulatory death
- Primary Endpoint
- Difference in delayed graft function duration between treatment and placebo groups
- Key Secondary Objectives
- Reduce hospitalization duration, improve kidney function markers, assess mortality rates
- Administration
- Intravenous infusion
- Maximum Daily Dose
- 50,000 IU
- Maximum Total Dose
- 75,000 IU
- Treatment Duration
- Up to 3 days
What is Alkaline Phosphatase (bRESCAP)?
Alkaline Phosphatase, also known by its product name bRESCAP, is a protein-based medication being studied for use in kidney transplant patients. It's important to note that this is a bovine (cow-derived) form of alkaline phosphatase, which means it comes from cows rather than being produced in a lab or derived from human sources.
Medical Conditions Treated
bRESCAP is being investigated for use in patients with end-stage kidney disease who are receiving kidney transplants from donors after circulatory death (DCD). End-stage kidney disease is a condition where a person's kidneys have stopped working well enough for them to survive without dialysis or a kidney transplant.
How It Works
The main goal of using bRESCAP is to prevent a complication called ischemia-reperfusion injury in deceased donor kidney transplantation. This type of injury can occur when blood supply returns to the kidney after a period without oxygen, which can happen during the transplant process. By preventing this injury, researchers hope to reduce the duration of delayed graft function (DGF), a situation where the transplanted kidney doesn't work immediately and the patient needs dialysis within the first week after transplant.
Potential Benefits
Researchers are studying whether bRESCAP can provide several benefits for kidney transplant patients, including:
- Shorter hospital stays after kidney transplantation
- Decreased need for long-term dialysis after transplant
- Improved kidney function in the first week after transplantation
- Better kidney perfusion (blood flow through the kidney) six days after transplant
- Improved kidney function at 3 months and 1 year after transplantation
- Reduced risk of transplant rejection within the first year
- Improved survival rates at 28 days, 90 days, and 1 year after transplant
Who Can Receive This Treatment?
As this treatment is still being researched, it's only available to certain patients participating in clinical trials. Currently, eligible patients are:
- Recipients of kidneys from donors after circulatory death (a specific type of deceased donor)
- Able to provide written informed consent
However, some people cannot participate in the study, including:
- Strict vegetarians (as the medication is derived from cows)
- People with a history of allergy to bovine (cow) proteins
How is it Administered?
bRESCAP is given as a solution for injection through intravenous (IV) infusion. This means it's delivered directly into the bloodstream through a vein. The maximum daily dose being studied is 50,000 international units (IU), with a maximum total dose of 75,000 IU over a treatment period of up to 3 days.
Ongoing Research
bRESCAP is currently being studied in a Phase 2 clinical trial. This means that while it has shown promise in earlier studies, it's still being tested to determine its effectiveness and safety in larger groups of patients. The results of this study will help researchers understand how well bRESCAP works and whether it should move on to larger, more definitive trials.
It's important to remember that while the potential benefits of bRESCAP are exciting, it's still an experimental treatment. Patients should always discuss their treatment options with their healthcare providers and consider all available information before making decisions about their care.